Detalhe da pesquisa
1.
Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossible.
Haematologica
; 2024 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38356448
2.
Identification of clinical factors impacting outcome in patients undergoing autologous hematopoietic cell transplantation after BEAM and TEAM conditioning.
Eur J Haematol
; 112(3): 350-359, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37823328
3.
Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed/refractory multiple myeloma: Extended follow-up subgroup analysis of the BOSTON trial.
Eur J Haematol
; 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38693052
4.
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network.
Lancet Oncol
; 24(6): e255-e269, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37269857
5.
In search for cure of multiple myeloma.
Haematologica
; 2023 Nov 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37981890
6.
An objective assessment in newly diagnosed multiple myeloma to avoid treatment complications and strengthen therapy adherence.
Haematologica
; 108(4): 1115-1126, 2023 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36325890
7.
Multidisciplinary tumor board analysis: validation study of a central tool in tumor centers.
Ann Hematol
; 102(3): 603-611, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36464695
8.
Clinical phenotype and outcome of persistent SARS-CoV-2 replication in immunocompromised hosts: a retrospective observational study in the Omicron era.
Infection
; 2023 Dec 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38095753
9.
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.
N Engl J Med
; 381(8): 727-738, 2019 08 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-31433920
10.
Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set.
Blood
; 136(26): 3033-3040, 2020 12 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-33367546
11.
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics.
Eur J Haematol
; 108(1): 73-83, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34496096
12.
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group.
Lancet Oncol
; 22(3): e105-e118, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33662288
13.
Comparison of the prognostic significance of 5 comorbidity scores and 12 functional tests in a prospective multiple myeloma patient cohort.
Cancer
; 127(18): 3422-3436, 2021 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34061991
14.
Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network.
Cancer
; 127(18): 3413-3421, 2021 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34181755
15.
Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations.
Br J Haematol
; 194(3): 496-507, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33724461
16.
Geriatric assessments and frailty scores in multiple myeloma patients: a needed tool for individualized treatment?
Curr Opin Oncol
; 33(6): 648-657, 2021 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34534141
17.
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma.
Haematologica
; 106(8): 2054-2065, 2021 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33792221
18.
2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde.
Haematologica
; 106(11): 2799-2812, 2021 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34261295
19.
Multidisciplinary tumor boards and their analyses: the yin and yang of outcome measures.
BMC Cancer
; 21(1): 173, 2021 Feb 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-33596881
20.
Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study.
BMC Cancer
; 21(1): 993, 2021 Sep 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34488662